Life-Threatening Wunderlich Syndrome Associated with Apixaban and the Complexity of Anticoagulation Management in Bleeding Patients: A Case Report
Keywords:Acute Kidney Injury, Anticoagulants/adverse effects, Hemorrage, Kidney Diseases/chemically induced, Rupture, Spontaneous
AbstractWunderlich syndrome is a rare and possibly life-threatening haemorrhagic syndrome presenting as spontaneous nontraumatic renal rupture with subcapsular and perinephric haemorrhage. Apixaban, a direct oral anticoagulant recommended in patients with atrial fibrillation, has previously been associated with atraumatic solid organ rupture but, to date, no case of apixaban-related Wunderlich syndrome has been reported. We report a rare case of Wunderlich syndrome associated with apixaban while addressing the difficulties face by clinicians when managing anticoagulation in bleeding patients.
Lowry LE, Goldner JA. Spontaneous splenic rupture associated with apixaban: a case report. J Med Case Rep. 2016;10:217.
Basnet S, Mohanty E, Mir I, Dhital R, Koirala A, Tachamo N. Atraumatic splenic rupture associated with apixaban. SAGE Open Med Case Rep. 2019;7:2050313X19832490.
Albi G, del Campo L, Tagarro D. Wünderlich’s syndrome: causes, diagnosis and radiological management. Clin Radiol. 2002;57:840-5.
Simkins A, Maiti A, Cherian SV. Wunderlich syndrome. Am J Med. 2017;130:e217-8.
Grubb SM, Stuart JI, Harper HM. Sudden onset flank pain: spontaneous renal rupture. Am J Emerg Med. 2017;35:1787.e1-3.
Aldughiman AW, Alsunbul A, Al-Gadheeb A, Almuaiqel M, Alzahrani A, Alzahrani T, et al. Does spontaneous renal hemorrhage mandate close surveillance for impending renal cell carcinoma? A case report and literature review. Int J Surg Case Rep. 2020;73:44-7.
Kinnear N, Hennessey DB, Douglass-Molloy H, Jack G. Life-threatening Wunderlich’s syndrome with concurrent clopidogrel use. BMJ Case Rep. 2016;2016:bcr2016216171.
Zhang JQ, Fielding JR, Zou KH. Etiology of spontaneous perirenal hemorrhage: a meta-analysis. J Urol. 2002;167:1593-6.
Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981-92.
Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, et al. ESC Scientific Document Group. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2021;42:373-498.
How to Cite
Copyright (c) 2023 Acta Médica Portuguesa
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All the articles published in the AMP are open access and comply with the requirements of funding agencies or academic institutions. The AMP is governed by the terms of the Creative Commons ‘Attribution – Non-Commercial Use - (CC-BY-NC)’ license, regarding the use by third parties.
It is the author’s responsibility to obtain approval for the reproduction of figures, tables, etc. from other publications.
Upon acceptance of an article for publication, the authors will be asked to complete the ICMJE “Copyright Liability and Copyright Sharing Statement “(http://www.actamedicaportuguesa.com/info/AMP-NormasPublicacao.pdf) and the “Declaration of Potential Conflicts of Interest” (http:// www.icmje.org/conflicts-of-interest). An e-mail will be sent to the corresponding author to acknowledge receipt of the manuscript.
After publication, the authors are authorised to make their articles available in repositories of their institutions of origin, as long as they always mention where they were published and according to the Creative Commons license.